Skip to main content

Integer Holdings Corporation (ITGR) Stock Analysis

Momentum Cont setup

HoldModerate Confidence

Healthcare · Medical Devices

Hold if already holding. Not a fresh buy at $88.16, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%); Analyst target reached - limited upside remaining.

Integer Holdings is a medical device CDMO manufacturing components and finished devices for Cardio & Vascular, Cardiac Rhythm Management, and Neuromodulation OEM customers from facilities in the U.S., Mexico, Ireland, and other countries. Top 3 customers (Abbott Laboratories,... Read more

$88.16+1.5% A.UpsideScore 4.8/10#37 of 40 Medical Devices
QualityF-score6 / 9FCF yield3.28%
Stop $81.99Target $89.48(resistance)A.R:R -0.3:1
Analyst target$97.22+10.3%9 analysts
$89.48our TP
$88.16price
$97.22mean
$84
$115

Hold if already holding. Not a fresh buy at $88.16, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%); Analyst target reached - limited upside remaining. Chart setup: Trend continuation, RSI 56, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.8/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst cluster(6), earnings proximity 74d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

Recent Developments — Integer Holdings Corporation

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Positive news sentiment (+0.71)
Risks
Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%)
Analyst target reached - limited upside remaining
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4)

Key Metrics

P/E (TTM)21.9
P/E (Fwd)13.0
Mkt Cap$3.0B
EV/EBITDA12.0
Profit Mgn7.6%
ROE8.6%
Rev Growth0.5%
Beta0.66
DividendNone
Rating analysts17

Quality Signals

Piotroski F6/9

Concentration Risks(10-K Item 1A)

  • HIGHCustomerAbbott Laboratories, Boston Scientific and Medtronic49%
    10-K Item 1: 'During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.'

Material Events(8-K, last 90d)

  • 2026-03-12Item 5.02LOW
    Per Cooperation Agreement with Irenic Capital dated March 9, 2026, James F. Flanagan and Irenic-designated Aaron Kapito appointed to Board. Two incumbent directors will not stand for re-election at 2026 Annual Meeting.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
2.6
Low model confidence on this dimension (33%).

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance
2.2
Bollinger
2.7
52w Position
3.8

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
1.0
Quality Rank
5.0
Value Rank
6.5
GatesA.R:R -0.3=NEGATIVEDeath cross (50MA < 200MA)Momentum 6.8>=5.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST CLUSTER(6)EARNINGS PROXIMITY 74d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARMomentum ContSuitability: Aggressive
RSI
56 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $77.05Resistance $91.31

Price Targets

$82
$89
A.Upside+1.5%
A.R:R-0.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Target reached (-4.1% upside)
! NEWS_MOD=+2: SELL_IF_HOLDING → HOLD_IF_HOLDING
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-07-30 (74d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ITGR stock a buy right now?

Hold if already holding. Not a fresh buy at $88.16, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%); Analyst target reached - limited upside remaining. Chart setup: Trend continuation, RSI 56, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $89.48 (+1.5%), stop $81.99 (−7.5%), A.R:R -0.3:1. Score 4.8/10, moderate confidence.

What is the ITGR stock price target?

Take-profit target: $89.48 (+1.5% upside). Target $89.48 (+1.5%), stop $81.99 (−7.5%), A.R:R -0.3:1. Stop-loss: $81.99.

What are the risks of investing in ITGR?

Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%); Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4).

Is ITGR overvalued or undervalued?

Integer Holdings Corporation trades at a P/E of 21.9 (forward 13.0). TrendMatrix value score: 6.3/10. Verdict: Hold.

What do analysts say about ITGR?

17 analysts cover ITGR with a consensus score of 3.7/5. Average price target: $97.

What does Integer Holdings Corporation do?Integer Holdings is a medical device CDMO manufacturing components and finished devices for Cardio & Vascular, Cardiac...

Integer Holdings is a medical device CDMO manufacturing components and finished devices for Cardio & Vascular, Cardiac Rhythm Management, and Neuromodulation OEM customers from facilities in the U.S., Mexico, Ireland, and other countries. Top 3 customers (Abbott Laboratories, Boston Scientific, Medtronic) collectively represented 49% of 2025 revenues.

Related stocks: GMED (Globus Medical, Inc.) · DXCM (DexCom, Inc.) · PODD (Insulet Corporation) · ENOV (Enovis Corporation) · ZBH (Zimmer Biomet Holdings, Inc.)